INTS News
Archived Headlines
- US IPO Week Ahead: More micro-caps after a big week for IPOs 02/10/23
- US IPO Week Ahead: IPO market heats up with solar trackers, lidar tech, and hypertension drugs 02/03/23
- Solid tumor biotech Intensity Therapeutics sets proposed price at $4.50 ahead of $8 million IPO 01/27/23
- US IPO Week Ahead: January closes out with a busy IPO calendar, led by energy company TXO 01/20/23
- Solid tumor biotech Intensity Therapeutics lowers share offering by 20% ahead of $8 million IPO 01/13/23
See more
US IPO Weekly Recap: Sizable deals close out the 2Q IPO market, led by thrift store Savers
Seven issuers began trading in the final week of June, six of which are eligible for inclusion in our IPO stats and four of which raised $100+ million. They were joined by one blank check company. The 2Q saw the IPO market end with much more momentum than it...read more
Solid tumor biotech Intensity Therapeutics prices IPO at $5, the high end of the range
Intensity Therapeutics, a Phase 2 biotech developing intratumoral injection therapies for cancer, raised $20 million by offering 3.9 million shares at $5, the high end of the range of $4 to $5. The company offered 0.7 million more shares than anticipated. ...read more
Solid tumor biotech Intensity Therapeutics revises terms ahead of $15 million IPO
Intensity Therapeutics, a Phase 2 biotech developing intratumoral injection therapies for cancer, raised the proposed deal size for its upcoming IPO on Thursday. In its latest filing, the company also disclosed financials for the three months ended March 31,...read more
US IPO Weekly Recap: Calendar is quieter than expected as more small IPOs join the pipeline
Two small issuers began trading this past week, only one of which was large enough to be included in our IPO stats, as several deals postponed (SODR, MGRX) or delayed (TRNR, INTS, NRXS). Two SPACs also priced. Eight IPOs submitted initial filings, the...read more